UNSPSC 51111761: Ranibizumab

This classification denotes an immunoconjugate with the molecular formula C2158H3282N562O681S12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZL1R02VT79, more generally known as ranibizumab. European Medicines Agency schedules ranibizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22314. The term RANIBIZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 18, no. 3, 2004, list 52. Most nations schedule ranibizumab under HS 30021091 and SITC 54163.

As of Q4 2014, RANIBIZUMAB remains the US FDA Preferred Term for this commodity. Ranibizumab bears US NLM identifiers UMLS ID C1566537 and NCI Concept Code C67562. SMILES: none.

UNSPSC 51111761 Ranibizumab, a Commodity code, does not align with the recent state and local solicitations tagged under it. The code nominally covers ranibizumab, a biopharmaceutical injection used in ophthalmology, yet the four most recent opportunities posted under this code solicit naloxone and drug deactivation systems, medical and first aid supplies, generic pharmaceuticals and OTC products, and direct-to-manufacturer prescription program capabilities — none of which involve ranibizumab or are ophthalmology-related. The mismatch suggests either systematic miscoding in the source procurement systems or that the code is being used as a catch-all for pharmaceutical and medical-supply procurement across state and local agencies without regard to the specific commodity name.

The recent opportunities show activity from a county health department (Seminole County, Florida), a state health commission (Texas HHS Commission), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (Minnesota MMCAP, serving state and local government facilities across multiple states including Oregon), with response dates ranging from March 2026 through July 2026. The Seminole County IFB for naloxone and drug deactivation systems (due July 26, 2026) and the Tampa Fire Department's ITB for medical and first aid supplies (due March 13, 2026, with an estimated contract value of $700,000) represent the most concrete procurement signals. The Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (response deadline March 26, 2026) and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026) indicate broader state-level interest in pharmaceutical supply chain restructuring and cost management. Given the absence of ranibizumab-specific recent activity and the consistent miscoding pattern across four distinct opportunities, the code shows little relevant current market signal for vendors selling the commodity it nominally represents.